Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

Rhea-AI Summary

Madrigal Pharmaceuticals (Nasdaq: MDGL) will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and can be accessed via the company’s Investor Relations Events page. A replay will be available after the event.

Key Figures

Conference date: March 3, 2026 Presentation time: 2:30 P.M. ET

2 metrics

Conference date March 3, 2026 TD Cowen 46th Annual Health Care Conference presentation date

Presentation time 2:30 P.M. ET Scheduled time for conference webcast presentation

Market Reality Check

Price: $440.00 Vol: Volume 535,325 vs 20-day ...

normal vol

$440.00 Last Close

Volume Volume 535,325 vs 20-day average 397,564 (relative volume 1.35x) indicates moderately elevated trading ahead of the conference. normal

Technical Shares at $437.79 are trading above the 200-day MA of $422.68 and sit between the $265 52-week low and $615 52-week high.

Peers on Argus

MDGL was up 0.64% with mixed moves across close biotech peers: VRNA +0.06%, ROIV...

MDGL was up 0.64% with mixed moves across close biotech peers: VRNA +0.06%, ROIV +2.06%, BPMC +0.09%, MRNA +3.28%, HALO -0.03%. No clustered sector momentum was detected.

Historical Context

5 past events · Latest: Feb 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Earnings results	Positive	-6.8%	Reported strong 2025 Rezdiffra sales and cash balance alongside key pipeline progress.
Feb 17	Inducement awards	Neutral	+4.9%	Granted 2,749 RSUs to five new non-executive employees under 2025 Inducement Plan.
Feb 11	Licensing deal	Positive	+0.5%	Exclusive global license for six siRNA programs targeting MASH with milestones and royalties.
Feb 11	Pipeline expansion	Positive	+0.5%	Expanded MASH pipeline beyond 10 programs anchored by Rezdiffra via Ribo agreement.
Feb 05	Inducement awards	Neutral	+3.1%	Issued 5,861 RSUs to 21 new non-executive employees under the 2025 Inducement Plan.

Pattern Detected

Recent MDGL news has generally aligned with price moves, though the strong 2025 results on Feb 19 saw a notable negative divergence.

Recent Company History

Over recent months, Madrigal has reported strong Rezdiffra-driven growth, with 2025 net sales of $958.4M and Q4 revenue of $321.1M. It expanded its MASH pipeline via siRNA licensing deals with upfront payments of $60M and milestones up to $4.4B. Multiple inducement equity grants were reported in early 2026. Against this backdrop, the TD Cowen conference appearance fits an ongoing investor-relations and visibility push rather than a new fundamental catalyst.

Market Pulse Summary

This announcement highlights Madrigal’s upcoming presentation at the TD Cowen health care conference...

Analysis

This announcement highlights Madrigal’s upcoming presentation at the TD Cowen health care conference on March 3, 2026 at 2:30 P.M. ET, with a live webcast and replay. It primarily signals ongoing investor-engagement efforts rather than a discrete clinical or financial catalyst. In context of recent strong Rezdiffra revenues and pipeline deals, investors may watch for any incremental commentary on commercialization trends, trial timelines, or strategic priorities.

AI-generated analysis. Not financial advice.

CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

When will Madrigal Pharmaceuticals (MDGL) present at the TD Cowen 46th Annual Health Care Conference?

Madrigal will present on Tuesday, March 3, 2026 at 2:30 P.M. ET. According to Madrigal, the company confirmed the date and time for its TD Cowen conference presentation.

How can investors watch Madrigal Pharmaceuticals (MDGL) present live on March 3, 2026?

Investors can watch the presentation via a live webcast accessible on Madrigal’s Investor Relations Events page. According to Madrigal, the webcast will stream live and is available from the company’s events page.

Will a replay of Madrigal Pharmaceuticals (MDGL) webcast be available after the TD Cowen conference?

Yes, a replay will be available after the event for those who miss the live webcast. According to Madrigal, the company will post a replay following the live presentation on its events page.

Where can I find the Madrigal Pharmaceuticals (MDGL) webcast link for the TD Cowen conference?

The webcast link is available on Madrigal’s Investor Relations Events page and the live stream page. According to Madrigal, viewers may access the live presentation via the company’s investor relations events listing.

What details did Madrigal Pharmaceuticals (MDGL) announce about its TD Cowen conference presentation on February 24, 2026?

Madrigal announced its participation, the March 3, 2026 2:30 P.M. ET presentation time, and that the session will be webcast with a replay. According to Madrigal, those are the confirmed logistics for the event.